Product Images Myrbetriq

This is a description for the medication Myrbetriq, containing the NDC code, expiration date, Lot number, dosage, and manufacturing information. It is in tablet form and should not be cut or crushed but swallowed whole. The directions for use are found in the package insert. The medication should be kept out of the reach of children and stored within the temperature range of 20-26°C. The text also contains a warning not to cut or crush the tablet, and an additional reference to the distributor.*

The text provides information about Myrbetriq, which is a medication containing mirabegron. It includes the National Drug Code, expiration date, dosage, manufacturer, and warnings. One should keep this medicine out of the reach of children and never cut or crush the tablet. The directions for use are available on the package insert. The drug must be stored at a temperature of 20-26°C but can be stored at excursions permitted to 15-30°C. The last line seems to be an address or contact information for a company.*

Myrbetriq is a medication used in the treatment of urinary incontinence. It comes in a package with a National Drug Code of 70518-2435-00 and an extended-release source NDC of 00469-2602-90. The medication is manufactured by Astellas Pharma US, Inc., Northbrook, IL 60082, and comes in a 50-mg tablet form. The product warns not to cut or crush the tablet, and the directions should be carefully followed. It is advised to store the product at a temperature between 20-26°C (63-77°F) with excursions ranging from 15-30°C (59-86°F).*

This text provides information on the PK fold change and 90% CI recommendations of CYP3A/Pgp inhibitors/inducers like Ketoconazole and Rifampicin, as well as other drugs like Solifenacin, Tamsulosin, and Metformin. The text suggests that for some of these drugs, no dose adjustment is necessary based on their AUC and Cmax values. The text also includes a chart showing the mean change relative to Mirabegron alone.*

This text provides information on the recommended PK fold change and 90% CI for different drugs when co-administered with CYP3A4 and CYP2D6 substrates. It includes details on the dosage adjustment and cautionary measures for some drugs such as Digoxin and Desipramine, when administered with substrate drugs. Additionally, the table provides data for mean changes relative to substrate alone.*

This is a table showing mean change from baseline for three different groups treated with either placebo or mirabegron at two different doses (25 mg and 50 mg). The data is presented for weeks 4, 8, and 12. There are missing values for some weeks and doses.*

Adjusted Change From Baseline data is represented in the table above, showing measurements at various time intervals (Baseline, Week 4, Week 8, Week 12, and EoT) for subjects who were administered with different doses of a placebo or medication (S+M25mg, M25mg, S+M50mg, and M50mg). The table uses symbols such as "o", "@", "[", and "]", and the percentages (%) to display the treatment outcomes.*

This is a chart that shows the adjusted change from baseline in percentages at different time points for two different treatment groups: one taking a placebo and the other taking a combination of drugs with doses of either 25mg or 50mg. The time points are at baseline, week 4, week 8, and week 12 (end of treatment).*